Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.

CVS replaces CEO Karen Lynch with PBM exec David Joyner

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

October 19, 2024

Takeda CEO Christophe Weber to step down following prolonged drop in company shares

Christophe Weber will step down as CEO of Takeda next year, the company announced Thursday, following a drop-off in its share price over the last

January 30, 2025

Cancer Immunotherapy Month – 2022 saw a record number of approvals – Pharmaceutical Technology

Source: GlobalData, Drugs Database (Accessed: 27 June 2023) © GlobalData. Note: The chart displays drugs by their first approval date. Over the last ten years,

July 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.